February 8, 2021
Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline
Chengdu, China, 8 February 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising CNY63m (~USD10m), it has already achieved positive animal data in its small molecule program targeting MYC overexpression.
The financing, by a small syndicate of undisclosed, experienced Chinese angel investors adds to the previous seed financing of CNY68.75m (~USD11m) and is being used to support further expansion of ACB’s proprietary screening libraries and discovery platforms, with the goal of progressing two of its programs towards IND enabling studies this year.
ACB is an international private company, commercialising discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research.
The Company is using its unique screening libraries and discovery platforms in cancer biology to uncover novel mechanisms to induce cancer cell death, without harming healthy cells. Synthetic lethality is possible when the same genetic changes that enable carcinogenesis also make the cancer cell overly dependent on specific pathways and proteins. Attacking these dependencies with drugs can yield dramatic anti-cancer effects, while leaving normal cells healthy. Synthetic lethality enables targeting of drivers of carcinogenesis that are not currently amenable to drug development.
The Company has five distinct synthetic lethality programs in drug development. These include:
- Oncogene enabled synthetic lethality (focused on MYC inhibition)
- Tumour suppressor synthetic lethality
- Polyploid cell synthetic lethality
- Centrosome amplification/delustering therapy
- Restoration of contact inhibition
ACB has invested in proprietary small molecule and natural product libraries, that comprise novel scaffolds of drug-like molecules and natural medicinal botanicals, with over 20,000 botanical samples already collected and curated. ACB’s small molecule libraries are based on novel scaffolds upon which further diversity can be assembled. These general-utility new scaffold-drug fragment (GUNS-DF) libraries, are being expanded and evolved through iterative screening/optimization processes for multiple phenotypic screening projects.
In the company’s lead MYC inhibition program, a novel chemical series with low nM activity has been identified in model cell lines. Already, functional activity of ACB’s lead ‘HJ’ compound series has been demonstrated in vitro that mimics inhibition of Aurora B kinase. Inhibition of Aurora B kinase is known to elicit synthetic lethality in cells overexpressing MYC. The synthetic lethal phenotype includes the induction of cell cycle arrest early in mitosis followed by accumulation of polyploid cells. ACB is further exploring a second MYC inhibitory compound series.
Founder, President, and CEO of ACB, Dr. Dun Yang, said, “With the additional financing, we are well placed to accelerate our synthetic lethal approach and to maximise the value of our libraries and pipeline. Already a provisional filing covering the novel library of HJ compounds has been completed and this is the first GUNS-DF library for which ACB has filed for PCT patent protection, testifying to the utility of our library technology platform. We expect to follow this with additional composition of matter filings as we progress our MYC and other discovery programs.”
ACB’s goal is to generate first-in-class oncology drugs for a broad range of indications (targeting over 30% of cancer patients), with a focus on therapies disabling previously untargeted mitotic regulators. Overexpression of MYC engenders vulnerability in mitosis and many other cellular processes. It is the most commonly deregulated oncoprotein, making targeting it through synthetic lethality an attractive strategy for cancer therapy.
Since its foundation in 2016, ACB has grown to almost 50 employees in Chengdu China, Hyderabad, India, San Francisco, USA, and St Andrews, UK.
About Anticancer Bioscience https://www.anticancerbio.com/
Anticancer Bioscience (ACB) is an international private company, commercialising discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131m (~USD21m) and has ~50 employees in Chengdu, China, Hyderabad, India, San Francisco, USA, and St Andrews, UK.

https://drugsoverthecounter.com/# over the counter sleep aids that work
humana over the counter best appetite suppressant over the counter
over-the-counter drug ivermectin over the counter walgreens
https://over-the-counter-drug.com/# econazole nitrate cream over the counter
antibiotics over the counter anthem over the counter catalogue
over the counter hearing aids econazole nitrate cream over the counter
cialis prescription S DIC may be conceptualized as shown on the right
fluconazole over the counter over the counter drugs
ivermectin over the counter antacids over-the-counter
best sleep aid over the counter scabies treatment over the counter walmart
over the counter flu medicine uhc over the counter essentials 2019
https://amoxil.science/# amoxicillin 500 mg without prescription
tretinoin over the counter uk
online pharmacy reddit
arimidex buy india
flomax 8 mg
allopurinol tablets nz
strattera medication
retin a cream buy australia
how to get retin a cheap
singulair price australia
flomax generic price
www canadianonlinepharmacy
https://doxycycline.science/# doxycycline without prescription
flomax for females
arimidex prescription
generic prozac
cheap lasix
propranolol pill 30 mg
lasix water pill
flomax 4 mg price
noroxin pill
lasix 10 mg tablet
can you buy retin a over the counter
azithromycin generic india
strattera 25
malegra dxt tablets
noroxin
colchicine 500 mcg tab
buy flomax online without prescription
Get here. Read information now.
ivermectin purchase
Prescription Drug Information, Interactions & Side. Cautions.
erectafil 2.5
buspar 90 mg daily
can you buy retin a without a prescription in europe
Read information now. Drug information.
https://stromectolst.com/# how much is ivermectin
What side effects can this medication cause? Get here.
Read information now. Comprehensive side effect and adverse reaction information.
stromectol price us
Drugs information sheet. earch our drug database.
furosemide 20 mg tabs
Read information now. Generic Name.
https://stromectolst.com/# ivermectin lotion price
Comprehensive side effect and adverse reaction information. Some are medicines that help people when doctors prescribe.
What side effects can this medication cause? Learn about the side effects, dosages, and interactions.
https://stromectolst.com/# stromectol price us
Read here. Cautions.
strattera 80 mg coupon
flomax for ed
Get information now. Read now.
stromectol uk
Medscape Drugs & Diseases. Drugs information sheet.
flomax us pharmacy
flomax 4mg cost
xenical diet pill
I was wondering, if your husband didn t have the obstruct kamagra australia mastrcard 40 now has three wins in four North American starts for owner trainer driver Larry Stalbaum
arimidex 1